Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Abstract Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX; MTX-IR) who had four poor prognostic factors (PPFs). Methods Patients with MTX...

Full description

Bibliographic Details
Main Authors: Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-10-01
Series:Rheumatology and Therapy
Subjects:
Filgotinib
Poor prognostic factors
Adalimumab
Methotrexate
Online Access:https://doi.org/10.1007/s40744-022-00498-x

Internet

https://doi.org/10.1007/s40744-022-00498-x

Similar Items